Roth Capital Says Amarin's Approval Provides Visibility for Neptune reiterates Buy rating and $10.30 price target
11:50 EDT 27 Jul 2012 | Thomson Reuters
This article has expired, however you can still
download the PDF.
Preview:
In a flash note to clients on Friday, Roth Capital Partners' analyst Joseph Pantginis, Ph.D.,says that Thursday's FDA approval for Amarin Corporation's (NASDAQ:AMRN) Vascepa bodes well for Neptune Technologies & Bioressources' (Nas...
Other Sources for this Article
More From BioPortfolio on "Roth Capital Says Amarin's Approval Provides Visibility for Neptune reiterates Buy rating and $10.30 price target"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
